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Introduction
Human thinking depends, ultimately, on the integrity of 
brain cell to brain cell communication. Any process that 
impairs this communication – whether it is congenital or 
acquired, static or degenerative, anatomic or metabolic – 
has devastating consequences for the health and well-
being of that person. People with intellectual disabilities 
endure socioeconomic and health disparities as a conse-
quence of their cognitive impairment [1]. Similarly, 
people with acquired cognitive impairments suﬀ  er losses 
in work and social status with economic and familial 
hard  ships. While the biopsychosocial barriers facing 
people with acquired and congenital cognitive impair-
ments must be addressed by society, knowledge of how to 
prevent or cure cognitive impairment also plays a role in 
society’s responsibility for their care.
Alzheimer’s dementia is a neurodegenerative disease of 
the brain causing progressive cognitive impairment 
aﬀ  ecting three distinct population groups: most adults 
with Down syndrome aged >50 years; an early-onset 
group comprising people aged <60 years with speciﬁ  c 
genetic predispositions; and the largest, so-called late-
onset group, a majority of the very older people. Th  e 
onset of Alzheimer’s dementia has profound implications 
for health, social and economic well-being of all the 
people in whom this disease develops. Th  is applies 
equally for people with pre-existing intellectual disability 
as well as those starting with normal cognition [2,3]. 
Knowledge of the cause or causes of Alzheimer’s disease 
contributes to under  stand  ing the processes of usual 
cognition and the cognitive changes, and potentially 
points research in the direction of disease prevention or 
cure.
In fundamental but as yet incomplete ways, studies of 
the cognitive skills, brains and genetics of people with 
Down syndrome have contributed to understanding 
processes not only of both normal and abnormal think-
ing, but also of cognitive changes and neuro  pathology in 
Alzheimer’s disease development in the general 
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processing of β-amyloid brain deposits associated with 
Alzheimer’s dementia in adults with Down syndrome, 
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amyloid precursor protein gene on chromosome 
21. The processes and genes responsible for tau 
hyperphosphorylation contributing to toxic brain 
deposits were additionally identifi  ed. With increasing 
sophistication in genetic experimental techniques, 
additional mechanisms associated with excessive 
amyloid deposits were postulated and tested in brains 
of people with Down syndrome and Alzheimer’s 
disease and in those with early-onset Alzheimer’s 
disease. This in turn led to the proposal and testing 
for particular genetic defects associated with familial 
early-onset Alzheimer’s disease. Nearly 200 genetic 
causes of early-onset types of Alzheimer’s disease 
have since been identifi  ed. Only a minority of these 
causes are on chromosome 21, although the aetiology 
of excess amyloid production remains fundamental 
to their pathogenesis. Knowledge of the pathogenic 
mechanisms of Alzheimer’s disease in predisposed 
families and in people with Down syndrome is a step 
closer to prevention or cure of this devastating disease.
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disease in the early-onset group. Moreover, studies on 
people with Down syndrome have provided the basis for 
hypotheses generation and testing of disease prevention 
or cure. Nevertheless, the story behind the aetiology of 
Alzheimer’s disease is far from ﬁ  nished.  Th  e present 
review examines what is known about the causes of and 
processes believed to underlie Alzheimer’s dementia in 
adults with Down syndrome, with a particular emphasis 
on how this research has helped in the understanding of 
early-onset Alzheimer’s disease in the general population. 
As part of this process, discussions on the common 
clinical endpoint of brain neuropathology in Alzheimer’s 
disease and on genotypic and phenotypic associations in 
Down syndrome are helpful.
Common clinical features of Alzheimer’s disease
In all three at-risk groups, Alzheimer’s disease is 
diagnosed by repeated clinical reviews over time. Patients 
have a history of development of multiple cognitive 
deﬁ  cits, including memory impairment. In addition, they 
must have one or more of the following deﬁ  cits: aphasia, 
apraxia, agnosia, or problems with executive functioning. 
Th  e deﬁ  cits must represent a signiﬁ  cant decline in the 
person’s previous level of functioning and interfere with 
social responsibilities and skills. Additionally, there is a 
progression of the symptoms over time. Other medical 
causes such as metabolic or endocrine causes, other 
intracerebral diseases, and mental illnesses should be 
considered, and have been excluded. Currently, there is 
no universally recommended biochemical test that 
conﬁ  rms the diagnosis in day-to-day clinical practice.
An important limitation in scientiﬁ  c endeavour is the 
diﬃ   culty of clinical assessment of dementia in individuals 
with Down syndrome compared with the general 
population. Tests used to conﬁ  rm dementia in the general 
population are not reliable or valid in populations with 
congenital intellectual disability. Cognitive assessment 
batteries and diagnostic criteria in populations with 
congenital intellectual disability are required to detect 
dementia in the early stages and to improve studies of 
risk factors [4]
Alzheimer’s disease starts to aﬀ  ect most adults with 
Down syndrome at about the age of 50 years (for reviews 
see [5,6]). In the early-onset group, the dementia can 
start as early as in one’s 40s [7]. Collectively, the early-
onset general population group accounts for about 1% of 
all cases of Alzheimer’s disease.
Common neuropathology in Alzheimer’s disease
Th   e three at-risk groups for Alzheimer disease also share 
common endpoint neuropathologic changes in the 
medial temporal lobe structures and cortical areas of the 
brain. Th   e mechanisms leading to these changes, 
how  ever, appear to diﬀ  er  signiﬁ   cantly between the 
groups. In other words, the cumulative brain lesions 
currently considered characteristic of Alzheimer’s disease 
should be considered as endpoints, rather than as 
deﬁ  ning aetiology of the disease [8].
Th   e endpoint lesions consist of neuritic plaques, extra-
cellular deposits of ﬁ   brillar β-amyloid surrounded by 
degenerating neuronal processes and terminals, intra-
neural neuroﬁ   brillary tangles primarily composed of 
abnormally phosphorylated tau protein, vascular β-
amyloidosis associated with ﬁ  brillar amyloid deposition 
within the vascular wall, inﬂ   ammation, and oxidative 
damage. It is important to highlight that two processes, 
excess β-amyloid deposition and tau hyperphosphylation, 
contribute to these endpoint changes. Th  ese processes 
are toxic, presumably because they interfere with cell-to-
cell communication via energy failure and with other 
possible mechanisms leading to neurotransmitter failure, 
synaptic and neuronal loss, deterioration of neuronal 
networks, and brain atrophy [9].
In populations of people with Down syndrome who 
develop dementia and in those with early-onset 
Alzheimer’s dementia, the characteristic brain lesions are 
hypothesised to develop because of various mechanisms 
leading to the overproduction of toxic changes and 
deposits, whereas in the older groups with Alzheimer’s 
disease there is predominance for failure of clearance 
mechanisms. Among the group of overproduction 
Alzheimer’s diseases there are multiple contributory 
path  ways to amyloid deposition and tau hyperphos-
phory  lation, and similarly there are, in turn, many 
mecha  nisms for the failure to clear group. Th  e  paradigm 
of overproduction versus impaired clearance of particular 
amyloid peptides and tau hyperphosphorylation com-
prises the basis of the so-called amyloid hypothesis of 
Alzheimer’s disease.
Early history of amyloid homology in Alzheimer’s 
disease and Down syndrome
It was the study of Alzheimer’s disease in individuals with 
Down syndrome that predominantly led to the develop-
ment of the amyloid hypothesis. It is nevertheless diﬃ   cult 
to deﬁ  ne the single precise paper in which the idea that 
Alzheimer’s disease in Down syndrome was ﬁ  rst linked 
with amyloid and then later a familial early-onset type of 
dementia. Rather, it was probably a series of published 
observations, experiments, and discoveries enabled by 
increased molecular and genomic technologies that led 
to the discovery of this association.
Zigman and colleagues’ historical review [5] cites a 
reference from 1876 [10] as the ﬁ  rst account of presenile 
dementia in an individual with Down syndrome. Forty 
years later, in 1907, the ﬁ  rst report of dementia (later 
renamed Alzheimer’s disease) in a woman with probable 
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[11]. Zigman and colleagues’ review [5] also cites 
references as early as the 1920s, 1940s and 1970s [12-14] 
describing what later became known to be characteristic 
brain neuropathologic changes of Alzheimer disease 
among individuals with Down syndrome. Trisomy 21 was 
discovered in 1959 as the genetic cause of Down syn-
drome [15], and in 2000 the full genome was elucidated 
[16].
Th  e study of Alzheimer’s disease in individuals with 
Down syndrome really accelerated in the 1980s. Around 
this time, for a variety of social reasons, disability issues 
became prominent across a whole range of disciplines 
including science. People with intellectual disabilities 
were increasingly more visible as they moved from 
institutional to supported community group homes. 
With the general improvement in living and social 
conditions of people with intellectual disabilities, their 
life expectancy improved and suddenly their ageing 
issues were considerations for economists, disability 
advocates, and health professionals [17]. For example, by 
the late 1980s the lifespan of people with Down syndrome 
increased from 9 years at the middle of the last century to 
at least middle age and older [18,19]. Interest and 
research into Down syndrome increased, and was 
adequately funded and facilitated by the establishment of 
dedicated brain banks of deceased individuals with Down 
syndrome (for example see [5]) and the development of 
mouse models of trisomy 21 [20]. Th  is turn of events 
coincided with a revolution in scientiﬁ  c genomic studies 
and technological skills.
In the early 1980s, the senile plaques in brains of people 
with dementia and in brains of people with Down 
syndrome were sequenced and identiﬁ  ed as identical β-
amyloid by Glenner and Wong [21] and by Masters and 
colleagues [22]. Assuming that the β-amyloid protein was 
a human gene product, Glenner and Wong postulated 
that the genetic defect of Alzheimer’s disease was thus 
localised on chromosome 21 [21]. Interestingly, about 10 
years earlier, the amyloid deposition noted in cerebral 
vessels in a patient with Down syndrome was assumed to 
be ‘merely an incidental aspect of the disorder’ [23].
In the late 1980s, using brain tissue from normal aged 
individuals, one with Alzheimer’s disease and one with 
Down syndrome, Robakis and colleagues found that the 
β-amyloid identiﬁ  ed by Glenner and Masters was cleaved 
post-translationally from a larger precursor, the so-called 
amyloid precursor protein (APP) [24,25] – a ﬁ  nding 
supported by Tanzi and colleagues [26] and Kang and 
colleagues [27]. In 1987, Kang and colleagues [27] and 
Goldgaber and colleagues [28] discovered that the APP 
protein from which the β-amyloid found in the plaques, 
tangles and blood vessel deposits in Alzheimer’s disease 
and Down syndrome derived was a product of a gene 
mapped to chromosome 21. Th  e  APP gene structure was 
identiﬁ  ed formally in 1990 by Yoshikai and colleagues 
[29]. Th  e APP gene was found to contain 19 exons and 
spanned more than 170 kb. Th   e gene had several isoforms 
generated by alternative splicing of exons, and these 
encoded diﬀ  erent β-amyloid proteins, each with diﬀ  ering 
pathological signiﬁ   cance. In 1990 the APP gene was 
isolated to the long arm of chromosome 21 (see review 
by Price and colleagues [30]), as postulated by Glenner 
and Wong [21]. Th   is position was reﬁ  ned by Jenkins and 
colleagues, who found that the APP gene is located 
within the region 21q11.2-q21.05 of chromosome 21 [31].
Individuals with Down syndrome due to trisomy 21 
would therefore have three copies of the APP gene with a 
presumed increase of gene product, and hence an 
increased risk for toxic β-amyloid deposition. Later 
studies conﬁ   rmed a 55% increase in the APP gene 
product [32]. Although the concept of a critical region on 
chromosome 21 has largely been discounted, it is 
interest  ing to note that the APP gene was later found to 
lie outside this region [33]. Normal individuals also have 
APP, but there is a maintained homeostasis of production 
and clearance of β-amyloid.
Gene dosage as a cause of early-onset Alzheimer’s 
disease
Given the gene dosage theory of Alzheimer’s disease in 
adults with Down syndrome, the earliest search for a 
cause for known cases of early-onset Alzheimer’s disease 
therefore started with chromosome 21. Using genetic 
linkage techniques available in 1987, St George-Hyslop 
and colleagues found evidence that a genetic cause of a 
familial early-onset Alzheimer’s disease gene was located 
on chromosome 21, but were disappointed later that year 
when, in another 40 familial cases, no duplication of 
chromosome 21 genes were found in familial or sporadic 
Alzheimer’s disease [26].
Nearly 10 years later, however, mutant APP genes and 
isolated trisomy APP genes were conﬁ  rmed and identi-
ﬁ   ed as a cause of early-onset Alzheimer’s disease, 
although only in a small number of familial cases of direct 
trisomy APP [34].
Th  ere was an understandable appeal of simplicity for 
two earlier hypotheses that the phenotypic features of 
Down syndrome were due to a simple gene dosage eﬀ  ect 
(that is, 1.5 times normal) of genes and only of those 
genes within a certain so-called critical region on the 
long arm of chromosome 21. Both of these hypotheses 
appear to be incorrect based on information gleaned 
from mouse models of Down syndrome and also from 
later genomic and phenotypic correlations of individuals 
with Down syndrome. Some genes are produced 1.5 
times more than usual, but others are reduced [20,35,36]. 
Th  e phenotypic features in trisomy 21 Down syndrome 
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intellectual disability and neo  natal hypotonia are present 
in close to 100% of individuals with Down syndrome, the 
expression of these features varies widely. Th  e  variability 
in phenotype is due to allelic heterogeneity for 
chromosome 21, epistatic inter  actions of chromosome 21 
genes with genes on other chromosomes or chromosome 
21, imprinting eﬀ  ects of gene expression associated with 
the parental origin of the third chromosome 21, and 
environmental eﬀ   ects including stochastic and other 
prenatal and postnatal events [33]. For those individuals 
with partial trisomy there are additional possibilities for 
phenotypic variability due to the partial aneuploidy 
interfering with the expression of genes nearby. Such 
apposition and the consequent potential change in the 
expression may generate pheno  typic variability unrelated 
to the genes in the aneupleudy region. Many studies (for 
example [33,37]) now provide evidence against a critical 
region as any speciﬁ  c part of chromosome 21 being both 
necessary and suﬃ   cient for Down syndrome.
As far as Alzheimer’s disease is concerned, however, 
the overexpression of APP from the extra normal APP 
gene in chromosome 21 is alleged to be a fundamental 
cause of Alzheimer’s disease in adults with Down syn-
drome. Th   is is consistent with knowledge of the metabo-
lism and cleavage processes that occur in APP in 
Alzheimer disease pathology; the increased APP pro-
duced by the triplicate gene results in increased substrate 
for toxic amyloid deposits. Th  e hypothesis for trisomy 
APP predisposing to Alzheimer’s disease pathology in 
individuals with Down syndrome was further supported 
by a case report from Prasher and colleagues [38]. Th  ey 
reported the case of a 78-year-old woman with Down 
syndrome with partial trisomy without Alzheimer’s disease 
on neuropsychological, magnetic resonance imaging, and 
neuropathic assessments. Th  e gene sequence for APP 
was present only in two copies of chromosome 21. At 
autopsy, the neuronal density for tau was normal, there 
were no excessive amyloid plaques, and amyloid angio-
pathy was not found.
The role of secretases in increased β-amyloid 
deposition
Th  e means of APP metabolism and pathogenic mecha-
nisms of the products of APP are summarised in several 
reviews and are relevant when considering factors that 
lead to excess toxic deposits of the APP products. APP 
undergoes post-translational proteolytic processing by α-
secretase, β-secretase or γ-secretase, which appear to 
confer diﬀ   ering toxicity to the β-amyloids produced 
[9,39,40].  Factors aﬀ   ecting these secretase activities 
impact on the type and amount of β-amyloid produced 
and are a potential cause for overproduction of toxic 
deposits. Th   e α-secretase generates shorter-chain soluble 
amyloid protein, amyloid β40, which until recently was 
thought possibly not as toxic. Th   e other two secretases, 
β-secretase and subsequent γ-secretase, generate longer 
APP components, amyloid β42 and amyloid β43, with 
deﬁ  nite amyloidogenic (toxic) features. Both the longer 
and shorter types of β-amyloid are increased in the brains 
of people with Down syndrome, but the longer β-amyloid 
deposits seem more common in people with Down 
syndrome and dementia compared with those without 
dementia [41]. Th  e gene locations for the β-secretase 
amyloid cleaving enzymes (BACE-1 and BACE-2) have 
been identiﬁ   ed: BACE-1 is on chromosome 14 and 
BACE-2 is on chromosome 21 [42].
It was noted that that the vast majority of the familial 
early-onset Alzheimer disease mutations conferred a 
similar biochemical phenotype: an increased ratio of 
cerebral amyloid β ending at position 42 as opposed to 
position 40. Among early-onset Alzheimer’s disease 
patients, this led to a search for mutations in the 
secretases, especially those which were responsible for 
the cleavage of longer β-amyloid proteins [43]. Proteases 
with proposed α-secretase function, one of which is 
mapped to a gene on the long arm of chromosome 21, 
has not been associated with Alzheimer’s disease. In 
contrast, cleavage at the β-secretase site is mediated by 
BACE-1 from the BACE-1 gene on chromosome 11q23, 
and a mutation of this gene has been implicated in 
familial early-onset Alzheimer’s disease. Th  e BACE-2 
gene is located on chromosome 21 [42], but no cases of 
familial early-onset Alzheimer’s disease have been found 
with this mutation alone. Th  ere are at least ﬁ  ve  γ-
secretase-related genes. Of these, mutations of the 
PSEN1, PSEN2 and NCSTN genes appear to be impli-
cated in the early-onset familial disease [43].
Th   e location of the amyloid-β synthesis may also play a 
role in plaque burden. APP is known to be cleaved within 
the cytoplasmic tail by caspases [44], especially if the 
brain suﬀ   ers from an ischaemic or acute excitotoxic 
event. Caspases play a dual role in the proteolytic pro-
cess  ing of APP with the resulting propensity for amyloid-
β peptide formation and apoptotic death of neurons in 
Alzheimer’s disease. Th   is feature may be speculated to be 
an added factor contributing to the severity of plaque 
burden in both Down syndrome and early-onset 
Alzheimer’s dementia.
Other mechanisms may indirectly or directly impact on 
the various secretase expressions, which in turn alters the 
APP cleavage and toxic potential. Baek and colleagues 
demonstrated that IL-1β may impact on the presenilin-
dependent (that is, γ-secretase-dependent) cleavage of 
APP in individuals with Alzheimer’s disease [45]. 
Interest  ingly, increased IL-1 expression has been found 
in brains of individuals with Down syndrome and 
Alzheimer’s disease [46]. IL-1, in addition to possibly 
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gliosis, which itself contributes to impaired brain cell to 
brain cell communication. Th   e gene encoding IL-1 is not 
on chromosome 21, however, and whether the increased 
IL-1 in Down syndrome and Alzheimer’s disease is a 
cause of or an eﬀ  ect of neuronal damage is not known. 
Cathepesin B provides a major contribution to the β-
secretase activity [47]; interestingly, this protein is 
elevated in Down syndrome cells [48].
Several groups have identiﬁ   ed an aberrant form of 
ubiquitin B in addition to APP and in neuroﬁ  brillary 
tangles, neuritic plaques, and neuropil threads in the 
cere  bral cortex of patients with Down syndrome and 
patients with Alzheimer’s disease [49-51]. Ubiquitin B is 
encoded on chromosome 9 and has been implicated in 
familial forms of Alzheimer’s disease. Ubiquitin B 
appears to contribute to tau hyperphosphorylation.
Th   ere is some evidence that accumulating mitochon  drial 
DNA mutations in aging adults with Down syn  drome and 
Alzheimer’s dementia contribute to worsen  ing dementia 
via the impact on increasing β-secretase activity and the 
accumulation of β-amyloid [52]. Th   e impact of the genetic 
or acquired mitochondrial DNA mutations may be 
fundamentally more relevant for older-age sporadic 
Alzheimer’s disease. Conceivably, however, such mutations 
could also inﬂ   uence the clinical perfor  mance of those 
individuals with early-onset Alzheimer’s disease.
Tau in Down syndrome and Alzheimer’s disease
A second necessary neuropathology of Alzheimer’s 
disease involves pathology in the neuronal cytoskeleton 
(for a review see [39]). Tau is a normal axonal protein 
that binds to microtubules. Tau phosphorylation is 
regulated by the balance between multiple protein 
kinases and phosphatases, and in normal circumstances 
this process promotes assembly and stabilises micro-
tubules. When tau is hyperphosphorylated, neurons 
exhi bit  ﬁ  brillary accumulations in the cytoplasm includ-
ing neuroﬁ  brillary pathology in cell bodies and proximal 
dendrites. Ultra  structurally, ﬁ  brillary inclusions represent 
intracellular accumulations of straight ﬁ  laments  and 
paired helical ﬁ  laments, both of which are composed of 
hyperphos  phory  lated isoforms of tau, a low-molecular-
weight microtubule-associated protein. Because hyper-
phos  phory  lated tau species bind poorly to microtubules 
and alter microtubular stability, their biochemical modiﬁ  -
cation could aﬀ  ect cytoskeletal constituents, intracellular 
transport, cellular geometry, and/or neuronal viability. 
Oxidative damage and protein glycosylation involving 
cytoskeleton components may also play a role. Eventually 
neuroﬁ  brillary tangle-bearing cells die, by mechanisms 
that involve apoptotic pathways.
An interesting feature, not yet completely explained, is 
the presence of β-amyloid and diﬀ  use  nonﬁ  brillar, 
amor  phous plaques in young people with Down 
syndrome who do not have any evidence of dementia. It 
is only when these plaques undergo degeneration with 
the appearance of neuroﬁ  brillary tangles in older people 
with Down syndrome that the development of clinical 
dementia occurs. What triggers the neurodegeneration is 
still topical (for review see [5]). Tau hyperphosphorylation 
is known to be the mechanism for the development of the 
ﬁ  brillary tangles, however, and thus is a necessary contri-
bution to the development of dementia. Some compelling 
evidence using Down syndrome mouse and human 
models suggests that individuals with Down syndrome 
produce an excess of certain protein kinases that directly 
and indirectly hyperphosphorylate tau [53,54]. Th  e 
minibrain gene mutation dual-speciﬁ  city  tyrosine 
phosphorylation-regulated kinase 1A (DYRK1A), 
mapped to chromosome 21q22.2, may explain the 
change. Neuroﬁ  brillary tangles have been found to be 
immunoreactive with antibodies detecting DYRK1A. A 
higher prevalence of mini-kinase neuroﬁ  brillary tangles 
in the brains of people with Down syndrome and people 
with early-onset Alzheimer’s disease suggest that the 
overexpression of the DYRK1A gene in trisomy 21 may 
be the factor modifying the onset and progression of 
neuroﬁ   brillary degeneration in Down syndrome 
[32,53,54].
Other factors aﬀ  ecting tau phosphorylation have been 
considered as potential contributory mechanisms for 
early-onset Alzheimer’s disease in Down syndrome. 
Genetic variants of the ubiquitin 1 gene, UBQLN1, on 
chromosome 9q22 appear to increase the risk of 
Alzheimer’s disease possible via its mechanism on PSEN1 
and PSEN2, but the gene is also considered a possible 
contributor to neuroﬁ   brillary degeneration, a process 
attributed to tau hyperphos  phorylation. Aberrant forms 
of ubiquitin along with the β-amyloid proteins have been 
found in the brains of individuals with Down syndrome 
and Alzheimer’s disease, but not in individuals with 
Down syndrome without Alzheimer’s disease [50,51]. 
Th  ere is some suggestive evidence of a familial risk of 
Alzheimer’s disease in individuals with UBQLN1 
variants, although this evi  dence was not strong for 
familial early-onset cases [49]. Interestingly, no general 
population familial early-onset forms associated with 
minibrain kinase abnormalities have been identiﬁ  ed.
Other risk factors for Alzheimer’s disease in Down 
syndrome and possible treatments
Increased age, oestrogen deﬁ   ciency, reduced cerebral 
reserve, hypercholesterolaemia, and the presence of 
multiple medical problems are raised as potential risk 
factors for the development of Alzheimer’s dementia in 
people with Down syndrome (see [5]). Th   ere have been 
no conclusive studies linking these risk factors to familial 
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apoprotein Eε allele status (on chromosome 19) appears 
primarily more relevant to older-age sporadic-onset 
Alzheimer’s disease. Nevertheless, the apoprotein Eε2 
variant may be confer a delay in onset or severity of 
Alzheimer’s disease in adults with Down syndrome [55].
Th   e amyloid hypothesis and its appealing simplicity in 
the framework of overproduction versus reduced clear-
ance, and the identiﬁ   cation of some of the genes 
responsible for these processes, opens the door for 
genetic or downstream intervention to prevent the onset 
of the disease. However, no treatments used in adults 
with Down syn  drome and dementia have yet been shown 
to prevent or ameliorate the onset of Alzheimer’s disease. 
Only a minority of people with familial early-onset 
disease have APP gene mutations, but models of the 
processes involved in the discovery of treatments for 
Alzheimer’s disease in people with Down syndrome, such 
as the amyloid hypothesis, will probably be of beneﬁ  t in 
the search for treatments for people with familial early-
onset Alzheimer’s disease.
Conclusion
Th  e study of Alzheimer’s disease in individuals with 
Down syndrome has assisted in the understanding of 
early-onset Alzheimer’s disease in many ways, but not 
enough to provide a basis for successful treatment or 
prevention of dementia. First, there was the recognition 
of the homology of the damaging amyloid protein in the 
brains of individuals with Down syndrome and 
Alzheimer’s disease and of that in those with early-onset 
Alzheimer’s disease. Th  e protein was further shown to 
derive from cleavage from an APP. Th  en there was the 
postulation that the gene encoding APP was situated on 
chromosome 21, which was later proved. Although few 
adults with early-onset Alzheimer’s disease necessarily 
had muta  tions or isolated trisomy of the APP gene, 
features and processes that somehow impaired the 
metabolism of APP and would result in its excessive 
production were sought and discovered. A second 
component of the Alzheimer disease neuro  pathology, the 
neuroﬁ   brillary tangles from tau hyper  phosphorylation, 
has been hypothesised in adults with Down syndrome to 
be at least partly due to another gene on chromosome 
21  –  DYRK1A,  a gene that encodes a protein kinase 
enzyme which promotes tau hyper  phosphorylation.
As a result of these studies, the hypothesis that 
Alzheimer’s disease was fundamentally due to an 
imbalance of production and clearance of toxic forms of 
amyloid and tau proteins was made. Th  e simultaneous 
development of gene technology and using the amyloid 
hypothesis led to the discovery of many mutations in 
other genes causing early-onset Alzheimer’s disease. For 
people with Down syndrome and Alzheimer’s disease 
and for those with early-onset Alzheimer’s disease, a 
common problem is the overproduction of the toxic 
deposits. To date, the majority of genetic defects in 
familial early-onset Alzheimer’s disease result in mecha-
nisms leading to overproduction of the amyloid protein 
rather than mecha  nisms causing tau hyper  phos  phory-
lation. In addi  tion to identiﬁ  cation of a range of causal 
genetic defects, an astounding variety of mechanisms of 
actions causing overproduction and direct toxicity or 
downstream damage has now been identiﬁ  ed.
Along the way, much has been learned about normal 
versus congenitally impaired cognitive processes and a 
vast array of neurodegenerative causes and processes. 
Generic processes underlying brain neurodegeneration 
and the roles of apoptotic pathways and factors that 
trigger such cascades, inﬂ  ammation, and immunity have 
been important byproducts of this study and search for 
similarity. Identi  ﬁ     cation of the mini-kinases has been 
particularly useful in the consideration of developmental 
intellectual disability. So far, however, the studies have 
not translated into signiﬁ   cant preventive or curative 
clinical strategies, despite the proposal of seemingly 
plausible treatments. Th   e story has not yet ﬁ  nished.
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